Stock Track | Novo-Nordisk A/S Soars 7.05% in Pre-Market After FDA Approves Wegovy Weight-Loss Pill

Stock Track17:08

Novo-Nordisk A/S (NVO) surged 7.05% in pre-market trading following the U.S. Food and Drug Administration's approval of its weight-loss pill, Wegovy. The pill is a tablet formulation of the company's existing injectable drug and marks the first oral GLP-1 therapy approved for weight management in the U.S.

The approval is expected to significantly expand Novo Nordisk's market reach, as the pill addresses needle hesitancy and offers a more convenient treatment option for patients. The company plans to launch the pill in early January, with a competitive pricing strategy of $149 per month for starter doses. This development could help Novo Nordisk regain ground lost to rival Eli Lilly in the booming obesity-drug market.

Analysts predict the Wegovy pill could generate substantial sales, with TD Cowen estimating nearly $2 billion in revenue by 2030. The approval also comes as Novo Nordisk seeks to revitalize its business after a challenging year marked by slowing sales and intense competition.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145256687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145256687","market":"nz","top_or_hot":-1,"title":"Stock Track | Novo-Nordisk A/S Soars 7.05% in Pre-Market After FDA Approves Wegovy Weight-Loss Pill","media":"Stock Track","content":"<p>Novo-Nordisk A/S (NVO) surged 7.05% in pre-market trading following the U.S. Food and Drug Administration's approval of its weight-loss pill, Wegovy. The pill is a tablet formulation of the company's existing injectable drug and marks the first oral GLP-1 therapy approved for weight management in the U.S.</p><p>The approval is expected to significantly expand Novo Nordisk's market reach, as the pill addresses needle hesitancy and offers a more convenient treatment option for patients. The company plans to launch the pill in early January, with a competitive pricing strategy of $149 per month for starter doses. This development could help Novo Nordisk regain ground lost to rival Eli Lilly in the booming obesity-drug market.</p><p>Analysts predict the Wegovy pill could generate substantial sales, with TD Cowen estimating nearly $2 billion in revenue by 2030. The approval also comes as Novo Nordisk seeks to revitalize its business after a challenging year marked by slowing sales and intense competition.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo-Nordisk A/S Soars 7.05% in Pre-Market After FDA Approves Wegovy Weight-Loss Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo-Nordisk A/S Soars 7.05% in Pre-Market After FDA Approves Wegovy Weight-Loss Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-23 17:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo-Nordisk A/S (NVO) surged 7.05% in pre-market trading following the U.S. Food and Drug Administration's approval of its weight-loss pill, Wegovy. The pill is a tablet formulation of the company's existing injectable drug and marks the first oral GLP-1 therapy approved for weight management in the U.S.</p><p>The approval is expected to significantly expand Novo Nordisk's market reach, as the pill addresses needle hesitancy and offers a more convenient treatment option for patients. The company plans to launch the pill in early January, with a competitive pricing strategy of $149 per month for starter doses. This development could help Novo Nordisk regain ground lost to rival Eli Lilly in the booming obesity-drug market.</p><p>Analysts predict the Wegovy pill could generate substantial sales, with TD Cowen estimating nearly $2 billion in revenue by 2030. The approval also comes as Novo Nordisk seeks to revitalize its business after a challenging year marked by slowing sales and intense competition.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1145256687","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145256687","pubTimestamp":1766480914,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo-Nordisk A/S (NVO) surged 7.05% in pre-market trading following the U.S. Food and Drug Administration's approval of its weight-loss pill, Wegovy. The pill is a tablet formulation of the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"个股追踪|FDA批准Wegovy减肥药后诺和诺德A/S盘前大涨7.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo-Nordisk A/S (NVO) surged 7.05% in pre-market trading following the U.S. Food and Drug Administration's approval of its weight-loss pill, Wegovy. The pill is a tablet formulation of the company's existing injectable drug and marks the first oral GLP-1 therapy approved for weight management in the U.S.The approval is expected to significantly expand Novo Nordisk's market reach, as the pill addresses needle hesitancy and offers a more convenient treatment option for patients. The company plans to launch the pill in early January, with a competitive pricing strategy of $149 per month for starter doses. This development could help Novo Nordisk regain ground lost to rival Eli Lilly in the booming obesity-drug market.Analysts predict the Wegovy pill could generate substantial sales, with TD Cowen estimating nearly $2 billion in revenue by 2030. The approval also comes as Novo Nordisk seeks to revitalize its business after a challenging year marked by slowing sales and intense competition.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145256687","isCrawlerRequest":true}